La cadena de opciones muestra datos clave de las opciones de acciones de Xilio Therapeutics a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Xilio Therapeutics..

Xilio Therapeutics (NASDAQ:XLO) Bolsa, Cadena de Opciones

Xilio Therapeutics

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

AADI

APTO

CADL

CARA

HUMA

MESO

MOBX

MTEM

NVNI

OCEA

PRFX

QUBT

ZCAR

FedEx sube un 8,7% con resultados sólidos y una nueva estrategia. Descubre otras acciones destacadas en premercado hoy.

Las acciones de FedEx (FDX) suben alrededor de un 9%; 20 acciones que se mueven en premercado

Xilio Therapeutics Inc

<p>Barclays  analyst Adrienne Yih   maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Overweight and lowers the price target from $68 to $59.</p>


News

Price Target

Analyst Ratings

URBN

Barclays Maintains Overweight on Urban Outfitters, Lowers Price Target to $59

Earnings

Earnings Misses

DRI HEALTHCARE TRUST Q1 Adj. EPS $0.43 Misses $0.51 Estimate, Sales $44.03M Miss $44.12M Estimate

<p>Barnwell Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRN#NYSE">BRN</a>) ("Barnwell" or the "Company") today urged shareholders to follow the recommendation by leading proxy advisory firm Institutional Shareholder Services Inc. ("ISS") in its May 7, 2025, report in which it recommended just one candidate, Heather Isidoro, from the slate put forward by Ned Sherwood and his affiliates (the "Sherwood Group").</p>


Management

Barnwell Industries Urges Shareholders To Vote In Accordance With ISS Recommendation And Reject Ned Sherwood's Attempt To Take Over the Company

<p>WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) reported quarterly earnings of $0.29 per share which missed the analyst consensus estimate of $0.34 by 13.53 percent. This is a 36.77 percent decrease over earnings of $0.47 per share from the same period last year.  The company reported quarterly sales of $18.80 million which missed the analyst consensus estimate of $20.43 million by 7.96 percent.  This is a 26.20 percent decrease over sales of $25.48 million the same period last year.</p>


WhiteHorse Finance Q1 Core net investment income per share $0.29 Misses $0.34 Estimate, Total investment income $18.80M Miss $20.43M Estimate

WhiteHorse Finance Q1 Adj. EPS $0.294 Misses $0.34 Estimate, Sales $18.80M Miss $20.43M Estimate

WIIM

NRGV

NRGV stock has given up its prior loss. Energy Vault Holdings shares were trading lower after the company reported worse-than-expected Q1 financial results.

<h3>Gainers</h3>
<ul>
<li><strong>GigaCloud Tech</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) stock moved upwards by 17.2% to $18.61 during Monday's after-market session. The market value of their outstanding shares is at $708.4 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>Superior Industries Intl</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) stock rose 8.88% to $0.87. The company's market cap stands at $25.1 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>Boqii Holding</strong> (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BQ#AMEX">BQ</a>) stock increased by 8.15% to $2.52. The market value of their outstanding shares is at $11.8 million. </li>
<li><strong>Aureus Greenway Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock moved upwards by 7.56% to $0.64. The market value of their outstanding shares is at $8.8 million. </li>
<li><strong>QVC Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGP#NASDAQ">QVCGP</a>) shares increased by 7.02% to $16.61. </li>
<li><strong>Vasta Platform</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) shares moved upwards by 5.82% to $4.18. The company's market cap stands at $335.1 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Wah Fu Education Gr</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) shares fell 8.0% to $1.49 during Monday's after-market session. The market value of their outstanding shares is at $6.6 million. </li>
<li><strong>Top Win International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) stock declined by 7.51% to $5.55. The company's market cap stands at $137.9 million. </li>
<li><strong>Chijet Motor Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CJET#NASDAQ">CJET</a>) shares decreased by 6.52% to $2.01. The company's market cap stands at $57.6 million. </li>
<li><strong>Netclass Technology</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTCL#NASDAQ">NTCL</a>) shares declined by 6.49% to $27.11. The market value of their outstanding shares is at $483.3 million. </li>
<li><strong>E-Home Household Service</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) shares decreased by 5.64% to $0.1. </li>
<li><strong>Leslies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) stock decreased by 5.59% to $0.75. The market value of their outstanding shares is at $139.0 million. The company's, Q2 earnings came out 2 days ago.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Movers

CJET

LESL

NTCL

QVCGP

TOPW

VSTA

WAFU

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Xilio Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XLO#NASDAQ">XLO</a>) stock moved upwards by 28.6% to $0.94 during Monday's after-market session. The market value of their outstanding shares is at $48.6 million. As per the press release, Q1 earnings came out 2 days ago. </li>
<li><strong>OptimizeRx</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) shares rose 20.01% to $10.99. The market value of their outstanding shares is at $203.2 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>NewGenIvf Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares moved upwards by 13.79% to $3.63. The company's market cap stands at $2.7 million. </li>
<li><strong>Passage Bio</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) shares rose 10.28% to $0.34. The company's market cap stands at $21.1 million. </li>
<li><strong>Harvard Bioscience</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HBIO#NASDAQ">HBIO</a>) shares increased by 10.13% to $0.39. The company's market cap stands at $17.1 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>Aspire Biopharma Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASBP#NASDAQ">ASBP</a>) shares increased by 9.09% to $0.36. The market value of their outstanding shares is at $17.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Polyrizon</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 88.0% to $0.04 during Monday's after-market session. </li>
<li><strong>Hepion Pharmaceuticals</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HEPA#NASDAQ">HEPA</a>) stock decreased by 33.28% to $0.21. The company's market cap stands at $2.3 million. </li>
<li><strong>Entero Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares fell 26.13% to $0.31. The company's market cap stands at $1.4 million. </li>
<li><strong>Accelerate Diagnostics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXDX#NASDAQ">AXDX</a>) stock declined by 25.43% to $0.1. The company's market cap stands at $2.5 million. </li>
<li><strong>Sangamo Therapeutics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) stock fell 15.36% to $0.63. The company's market cap stands at $142.0 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>Klotho Neurosciences</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) shares decreased by 10.06% to $0.16. The company's market cap stands at $4.4 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ASBP

AXDX

ENTO

HBIO

HEPA

KLTO

NIVF

OPRX

PASG

PLRZ

SGMO

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li><strong>Lichen International</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) stock moved upwards by 134.8% to $8.17 during Monday's after-market session. The company's market cap stands at $4.8 million. </li>
<li><strong>Euro Tech Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLWT#NASDAQ">CLWT</a>) stock rose 59.09% to $2.1. The company's market cap stands at $16.2 million. </li>
<li><strong>VirTra</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTSI#NASDAQ">VTSI</a>) stock increased by 18.97% to $5.58. The market value of their outstanding shares is at $62.8 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>Dragonfly Energy Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DFLI#NASDAQ">DFLI</a>) stock increased by 15.86% to $0.58. The company's market cap stands at $4.3 million. </li>
<li><strong>WANG &amp; LEE Group</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) shares moved upwards by 15.18% to $0.29. The company's market cap stands at $6.0 million. </li>
<li><strong>Microvast Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) stock increased by 10.9% to $2.65. The company's market cap stands at $863.0 million. As per the news, the Q1 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>3D Sys</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) stock declined by 18.7% to $2.07 during Monday's after-market session. The company's market cap stands at $280.9 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>Energy Vault Holdings</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRGV#NYSE">NRGV</a>) stock declined by 13.09% to $0.93. The company's market cap stands at $143.4 million. The company's, Q1 earnings came out today. </li>
<li><strong>TPI Composites</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPIC#NASDAQ">TPIC</a>) shares declined by 13.05% to $0.86. The company's market cap stands at $40.9 million. The company's, Q1 earnings came out today. </li>
<li><strong>Jayud Global Logistics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) stock declined by 11.33% to $0.32. The company's market cap stands at $30.3 million. </li>
<li><strong>Globavend Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GVH#NASDAQ">GVH</a>) shares fell 10.16% to $1.15. The company's market cap stands at $17.1 million. </li>
<li><strong>Intelligent Living</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILAG#NASDAQ">ILAG</a>) shares decreased by 9.82% to $0.36. The company's market cap stands at $6.5 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CLWT

DFLI

ILAG

LICN

MVST

TPIC

VTSI

WLGS

12 Industrials Stocks Moving In Monday's After-Market Session

Brinker International, Appoints Aaron White To Executive Vice President, COO, And Chief People Officer For The Company's Restaurant Brands, Chili's Grill & Bar And Maggiano's Little Italy

<h3>Gainers</h3>
<ul>
<li><strong>Upland Software</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPLD#NASDAQ">UPLD</a>) shares moved upwards by 7.7% to $3.06 during Monday's after-market session. The company's market cap stands at $87.1 million. The company's, Q1 earnings came out today. </li>
<li><strong>Auddia</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUUD#NASDAQ">AUUD</a>) shares increased by 7.49% to $4.16. The market value of their outstanding shares is at $2.1 million. </li>
<li><strong>Key Tronic</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTCC#NASDAQ">KTCC</a>) shares moved upwards by 6.65% to $2.5. The market value of their outstanding shares is at $26.8 million. The company's, Q3 earnings came out 4 days ago. </li>
<li><strong>Iveda Solutions</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVDA#NASDAQ">IVDA</a>) stock increased by 6.36% to $2.34. The market value of their outstanding shares is at $6.5 million. </li>
<li><strong>Inseego</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSG#NASDAQ">INSG</a>) stock moved upwards by 5.23% to $8.24. The company's market cap stands at $123.6 million. As per the news, the Q1 earnings report came out 2 days ago. </li>
<li><strong>Cambium Networks</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMBM#NASDAQ">CMBM</a>) stock moved upwards by 4.84% to $0.5. The company's market cap stands at $14.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li><strong>Microvision</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVIS#NASDAQ">MVIS</a>) stock fell 16.5% to $1.01 during Monday's after-market session. The market value of their outstanding shares is at $248.2 million. As per the press release, Q1 earnings came out today. </li>
<li><strong>Gryphon Digital Mining</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) stock decreased by 11.27% to $1.26. The company's market cap stands at $87.3 million. </li>
<li><strong>Sonim Technologies</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) shares fell 10.74% to $1.33. The company's market cap stands at $6.4 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>Rigetti Computing</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) stock declined by 9.36% to $10.47. The company's market cap stands at $3.0 billion. The company's, Q1 earnings came out today. </li>
<li><strong>Indie Semiconductor</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) shares fell 9.06% to $2.41. The market value of their outstanding shares is at $472.8 million. As per the news, the Q1 earnings report came out today. </li>
<li><strong>X3 Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XTKG#NASDAQ">XTKG</a>) stock decreased by 8.93% to $1.02. The market value of their outstanding shares is at $14.0 million.<br />
<strong>See Also:</strong> <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AUUD

CMBM

GRYP

INDI

INSG

IVDA

KTCC

MVIS

RGTI

SONM

UPLD

XTKG

12 Information Technology Stocks Moving In Monday's After-Market Session

<p>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) reported quarterly losses of $(0.08) per share. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year.</p>


BYSI

BeyondSpring Q1 EPS $(0.08) Down From $0.11 YoY

<p>Barclays  analyst Adrienne Yih   maintains Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) with a Equal-Weight and lowers the price target from $8 to $6.</p>


Barclays Maintains Equal-Weight on Under Armour, Lowers Price Target to $6

<p>VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate VerifyMe to report an <strong>earnings per share</strong> (EPS) of $-0.07.</p>
<p>Investors in VerifyMe are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 6.5% drop in the share price on the subsequent day.</p>
<p>Here's a look at VerifyMe's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.04</td>
<td>-0.10</td>
<td>-0.09</td>
<td>-0.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.05</td>
<td>-0.06</td>
<td>-0.03</td>
<td>-0.05</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-6.0%</td>
<td>-9.0%</td>
<td>2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747083895_0.png" alt="eps graph" /></p>
<h3>VerifyMe Share Price Analysis</h3>
<p>Shares of VerifyMe were trading at $0.765 as of May 09. Over the last 52-week period, shares are down 51.31%.  Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. </p>
<h3>Insights Shared by Analysts on VerifyMe</h3>
<p>For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on VerifyMe.</p>
<p>A total of 1 analyst ratings have been received for VerifyMe, with the consensus rating being Outperform. The average one-year price target stands at $1.25, suggesting a potential 63.4% upside.</p>
<h3>Understanding Analyst Ratings Among Peers</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of  and MultiSensor AI Holdings, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for MultiSensor AI Holdings, with an average 1-year price target of $2.5, suggesting a potential 226.8% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for  and MultiSensor AI Holdings, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>VerifyMe</td>
<td>Outperform</td>
<td>-12.07%</td>
<td>$2.42M</td>
<td>-4.89%</td>
</tr>
<tr>
<td>MultiSensor AI Holdings</td>
<td>Buy</td>
<td>-13.26%</td>
<td>$1.06M</td>
<td>-21.40%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>VerifyMe underperforms its peers in revenue growth and gross profit, ranking at the bottom for both metrics. Its return on equity is also negative, indicating poor performance compared to peers. Overall, VerifyMe lags behind its peers in key financial metrics, suggesting potential challenges in profitability and growth.</p>
<h3>Unveiling the Story Behind VerifyMe</h3>
<p>VerifyMe Inc together with its subsidiaries, is a traceability and customer support services provider using specialized software and process technology. The company operates a Precision Logistics Segment and an Authentication Segment to provide specialized logistics for time-and-temperature sensitive products, as well as item-level traceability, anti-diversion and anti-counterfeit protection, brand protection and enhancement technology solutions. It Generates the majority of its revenue from the Precision Logistics Segment. Through its Precision Logistics segment, it provides a value-added service for sensitive parcel management driven by a proprietary software platform that provides predictive analytics from key metrics such as pre-shipment weather analysis, flight-tracking, and Others.</p>
<h3>Understanding the Numbers: VerifyMe's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> VerifyMe's revenue growth over 3 months faced difficulties. As of 31 December, 2024, the company experienced a decline of approximately <strong>-12.07%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> VerifyMe's net margin excels beyond industry benchmarks, reaching <strong>-6.54%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> VerifyMe's ROE excels beyond industry benchmarks, reaching <strong>-4.89%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> VerifyMe's ROA excels beyond industry benchmarks, reaching <strong>-3.24%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> VerifyMe's debt-to-equity ratio is below the industry average at <strong>0.22</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<p><a href="https://www.benzinga.com/quote/VRME/earnings"><strong>To track all earnings releases for VerifyMe visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


VRME

Earnings Outlook For VerifyMe

<p>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Adaptimmune Therapeutics to report an <strong>earnings per share</strong> (EPS) of $-0.17.</p>
<p>The market awaits Adaptimmune Therapeutics's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Overview of Past Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.15, leading to a 3.86% increase in the share price on the subsequent day.</p>
<p>Here's a look at Adaptimmune Therapeutics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.15</td>
<td>-0.13</td>
<td>-0.08</td>
<td>-0.10</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.30</td>
<td>-0.07</td>
<td>0.24</td>
<td>-0.18</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>4.0%</td>
<td>-23.0%</td>
<td>-4.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747083883_0.png" alt="eps graph" /></p>
<h3>Market Performance of Adaptimmune Therapeutics's Stock</h3>
<p>Shares of Adaptimmune Therapeutics were trading at $0.2926 as of May 09. Over the last 52-week period, shares are down 74.33%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/ADAP/earnings"><strong>To track all earnings releases for Adaptimmune Therapeutics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ADAP

A Look Ahead: Adaptimmune Therapeutics's Earnings Forecast

<p>Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Marchex to report an <strong>earnings per share</strong> (EPS) of $-0.02.</p>
<p>Investors in Marchex are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.</p>
<p>It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS missed by $0.01, leading to a 7.14% increase in the share price on the subsequent day.</p>
<p>Here's a look at Marchex's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.02</td>
<td>0</td>
<td>-0.01</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.03</td>
<td>-0.01</td>
<td>-0.01</td>
<td>-0.02</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>7.000000000000001%</td>
<td>-4.0%</td>
<td>-3.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747083871_0.png" alt="eps graph" /></p>
<h3>Tracking Marchex's Stock Performance</h3>
<p>Shares of Marchex were trading at $1.39 as of May 09. Over the last 52-week period, shares are up 9.7%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MCHX/earnings"><strong>To track all earnings releases for Marchex visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MCHX

An Overview of Marchex's Earnings

<p>BK Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BKTI#AMEX">BKTI</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect BK Technologies to report an <strong>earnings per share</strong> (EPS) of $0.44.</p>
<p>Anticipation surrounds BK Technologies's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Historical Earnings Performance</h3>
<p>The company's EPS beat by $0.26 in the last quarter, leading to a 12.5% increase in the share price on the following day.</p>
<p>Here's a look at BK Technologies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.61</td>
<td>0.71</td>
<td>0.55</td>
<td>0.3</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>12.0%</td>
<td>0.0%</td>
<td>6.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>
</p>
<h3>BK Technologies Share Price Analysis</h3>
<p>Shares of BK Technologies were trading at $44.91 as of May 09. Over the last 52-week period, shares are up 236.3%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on BK Technologies</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on BK Technologies.</p>
<p>With 2 analyst ratings, BK Technologies has a consensus rating of Buy. The average one-year price target is $45.5, indicating a potential 1.31% upside.</p>
<h3>Peer Ratings Overview</h3>
<p>In this analysis, we delve into the analyst ratings and average 1-year price targets of Ondas Holdings and Lantronix, three key industry players, offering insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Analysts currently favor an Buy trajectory for Ondas Holdings, with an average 1-year price target of $2.5, suggesting a potential 94.43% downside.</li>
<li>Analysts currently favor an Buy trajectory for Lantronix, with an average 1-year price target of $3.83, suggesting a potential 91.47% downside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Ondas Holdings and Lantronix, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>BK Technologies</td>
<td>Buy</td>
<td>9.93%</td>
<td>$7.38M</td>
<td>13.10%</td>
</tr>
<tr>
<td>Ondas Holdings</td>
<td>Buy</td>
<td>-16.77%</td>
<td>$883.50K</td>
<td>-73.14%</td>
</tr>
<tr>
<td>Lantronix</td>
<td>Buy</td>
<td>-15.87%</td>
<td>$13.28M</td>
<td>-3.02%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>BK Technologies is positioned at the top for Revenue Growth among its peers. In terms of Gross Profit, BK Technologies is also leading the group. However, BK Technologies is at the bottom for Return on Equity compared to its peers.</p>
<h3>Get to Know BK Technologies Better</h3>
<p>BK Technologies Corp a holding company, operates through its subsidiary, BK Technologies, Inc., specializing in designing, manufacturing, and marketing wireless communications equipment. Its Radio business unit offers two-way land mobile radios (LMRs) serving government and public safety markets, as well as industrial and commercial enterprises. The SaaS business unit focuses on public safety smartphone applications, enhancing first responders' safety and efficiency. The BKRplay application, tethered to BK radios, amplifies user capabilities, expanding the reach of their radio sales. Its product portfolio consists of two-way land mobile radios, handheld radios, radios installed in vehicles.</p>
<h3>Unraveling the Financial Story of BK Technologies</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Positive Revenue Trend:</strong> Examining BK Technologies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>9.93%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> BK Technologies's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>20.4%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> BK Technologies's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>13.1%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> BK Technologies's ROA excels beyond industry benchmarks, reaching <strong>7.47%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.04</strong>.</p>
<p><a href="https://www.benzinga.com/quote/BKTI/earnings"><strong>To track all earnings releases for BK Technologies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BKTI

What's Next: BK Technologies's Earnings Preview

<p>Southland Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SLND#AMEX">SLND</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-13. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<p>Analysts expect Southland Holdings to report an <strong>earnings per share</strong> (EPS) of $-0.37.</p>
<p>Southland Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Earnings History Snapshot</h3>
<p>The company's EPS beat by $0.40 in the last quarter, leading to a 6.29% increase in the share price on the following day.</p>
<p>Here's a look at Southland Holdings's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.49</td>
<td>-0.09</td>
<td>0.02</td>
<td>-0.14</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.09</td>
<td>-1.14</td>
<td>-0.96</td>
<td>-0.01</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>-22.0%</td>
<td>5.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747083844_0.png" alt="eps graph" /></p>
<h3>Performance of Southland Holdings Shares</h3>
<p>Shares of Southland Holdings were trading at $3.5 as of May 09. Over the last 52-week period, shares are down 27.47%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/SLND/earnings"><strong>To track all earnings releases for Southland Holdings visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


SLND

Examining the Future: Southland Holdings's Earnings Outlook

<p><strong>Macrogenics</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNX#NASDAQ">MGNX</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.</p>
<p>Analysts estimate that Macrogenics will report an <strong>earnings per share</strong> (EPS) of $-0.69. </p>
<p>Anticipation surrounds Macrogenics's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Earnings History Snapshot</h3>
<p>During the last quarter, the company reported an EPS beat by $0.34, leading to a 5.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at Macrogenics's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.59</td>
<td>0.21</td>
<td>-0.59</td>
<td>-0.64</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.25</td>
<td>0.90</td>
<td>-0.89</td>
<td>-0.84</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-5.0%</td>
<td>11.0%</td>
<td>-7.000000000000001%</td>
<td>-77.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1747083832_0.png" alt="eps graph" /></p>
<h3>Tracking Macrogenics's Stock Performance</h3>
<p>Shares of Macrogenics were trading at $1.43 as of May 09. Over the last 52-week period, shares are down 64.27%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/MGNX/earnings"><strong>To track all earnings releases for Macrogenics visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MGNX

A Look at Macrogenics's Upcoming Earnings Report

<p>AST SpaceMobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 25 percent decrease over losses of $(0.16) per share from the same period last year.  The company reported quarterly sales of $718.00 thousand which missed the analyst consensus estimate of $4.20 million by 82.90 percent.  This is a 43.60 percent increase over sales of $500.00 thousand the same period last year.</p>


ASTS

AST SpaceMobile Q1 EPS $(0.20) Misses $(0.18) Estimate, Sales $718.00K Miss $4.20M Estimate

Health Care

Press Releases

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Contracts

AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Xilio Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2024 Financial Results

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite Stable Colorectal Cancer at the 2025 ASCO Annual Meeting

Markets

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2025 Financial Results

Comments

Xilio Therapeutics

Xilio Therapeutics (XLO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL